Evaluating the performance of a clinicopathological prognostic nomogram and utility of the 40-gene expression profile (40-GEP) test in refining risk of metastasis in high-risk cutaneous squamous cell carcinoma (HR-cSCC) patients

• A. Jambusaria-Pahlajani,
• J. Cañueto,
• C. Cardona-Machado,
• A. Prasai,
• C. Bailey,
• J. Siegel,
• A. Fitzgerald,
• E. Vetto,
• E. Ruiz

Affiliations

A. Jambusaria-Pahlajani

Dell Medical School at the University of Texas, Division of Dermatology, Austin, Texas, United States of America

J. Cañueto

Complejo Asistencial Universitario de Salamanca, Department of Dermatology, Salamanca, Spain; Instituto de Biología Celular y Molecular de Cáncer (CIC-IBMCC)-CSIC/USAL, Salamanca, Spain

C. Cardona-Machado

Instituto de Biología Celular y Molecular de Cáncer (CIC-IBMCC)-CSIC/USAL, Salamanca, Spain; Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain

A. Prasai

Castle Biosciences Inc, R & D, Friendswood, Texas, United States of America

C. Bailey

Castle Biosciences Inc, Bioinformatics, Friendswood, Texas, United States of America

J. Siegel

Castle Biosciences Inc, Bioinformatics, Friendswood, Texas, United States of America

A. Fitzgerald

Castle Biosciences Inc, R & D, Friendswood, Texas, United States of America

E. Vetto

Castle Biosciences Inc, R & D, Friendswood, Texas, United States of America

E. Ruiz

Brigham and Women's Hospital, Harvard Medical School, Department of Dermatology, Boston, Massachusetts, United States of America